1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. CANCER CACHEXIA MARKET, BY THERAPEUTICS
5.1. Introduction
5.2. Progestogens
5.3. Corticosteroids
5.4. Combination Therapy
5.5. Others
6. CANCER CACHEXIA MARKET, BY MECHANISM OF ACTION
6.1. Introduction
6.2. Appetite Stimulators
6.3. Weight Loss Stabilizers
7. CANCER CACHEXIA MARKET, BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Retail Pharmacy
7.4. Online Pharmacy
8. CANCER CACHEXIA MARKET, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. United Kingdom
8.4.2. Germany
8.4.3. France
8.4.4. Spain
8.4.5. Others
8.5. The Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Israel
8.5.4. Others
8.6. Asia Pacific
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
10. COMPANY PROFILES
10.1. Actimed Therapeutics
10.2. Pephexia Therapeutics
10.3. Pfizer
10.4. Ono Pharma
10.5. Helsinn Group
10.6. Merck KGaA
10.7. Aveo Oncology
10.8. Tetra Bio-Pharma